EP 3227318 A1 20171011 - DPP4 IMMUNOADHESIN COMPOSITIONS AND METHODS
Title (en)
DPP4 IMMUNOADHESIN COMPOSITIONS AND METHODS
Title (de)
DPP4-IMMUNOADHÄSINZUSAMMENSETZUNGEN UND VERFAHREN
Title (fr)
COMPOSITIONS D'IMMUNOADHÉSINE DPP4 ET PROCÉDÉS
Publication
Application
Priority
- US 201462124011 P 20141205
- US 2015064142 W 20151205
Abstract (en)
[origin: WO2016090345A1] Described herein fusion proteins comprising modified DPP4 binding sequence and the Fc of a human immunoglobulin, related compositions, and related methods for inhibiting MERS- CoV infection. In addition to the improved potency, the modified DPP4-Fc is also expected to have superior pharmacokinetics, as Fc will confer a long circulating half-life and the ability to be delivered to airway mucosal surfaces, the site of MERS-CoV infection. Unlike antibodies against MERS-CoV, a DPP4-Fc and the modified DPPR-Fc decoy of the invention will not subject the virus to selection for neutralization escape mutants, as any mutation that decreases binding to the decoy will decrease binding to the native receptor, resulting in an attenuated virus.
IPC 8 full level
A61K 31/14 (2006.01); A61K 39/215 (2006.01); A61K 39/42 (2006.01); C07K 14/165 (2006.01); C07K 14/47 (2006.01); C07K 16/10 (2006.01); C07K 19/00 (2006.01); C12N 15/63 (2006.01); C12P 21/02 (2006.01)
CPC (source: EP)
A61K 39/12 (2013.01); C12N 9/485 (2013.01); C12Y 304/14005 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); C12N 2770/20011 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2016090345 A1 20160609; CA 2969891 A1 20160609; EP 3227318 A1 20171011; EP 3227318 A4 20181212
DOCDB simple family (application)
US 2015064142 W 20151205; CA 2969891 A 20151205; EP 15866344 A 20151205